Organon and MRC Technology sign antibody development agreement
26-Jul-2007
"Organon has been stepping up its efforts to discover and develop novel biotherapeutics for oncology and auto-immune disorders. The collaboration with MRCT on its well-validated antibody humanization technology is a further step towards becoming effective biotherapeutic drug hunters," said David Nicholson, EVP of R&D at Organon.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.